Real-world long-term #AF ablation outcomes on a highly diverse cohort of 3,500 patients (96% retention) from our home grown #ITHACA-database
🗝️ finding ➡️ persistent AF patients who are AF free at 1-year have similar outcomes to paroxysmal patients thereafter
@NorthwellHealth@DimitriVarrias@kcole_12@JCardioEP@DrBradleyKnight
🔗 https://t.co/FXzN0DduAX
Utilization of #AI based tools for delineating cardiac structures with ICE during #AblateVT cases as part of #FIH trials with new @AbbottCardio exceeded expectations - rapid definition of valves, paps in LV:
Huge thank you to our CVT Chairs, Laura Ogle, MSN, RN, AGACNP-BC, and @kcole_12 , MPH, RN, CCRC, for their leadership in putting together an incredible CVT Symposium! And a special shoutout to Kristie for also taking the stage as a speaker!
Mastery of ablation biophysics - will this become a lost art in era of PFA? Great presentation by #DrJoshMoss from @UCSFCardiology with lucid explanation of core concept of current density for lesion formation.
@JorgeERomeroMD@True_EP
@drjohnm@MelbourneEPdoc@nntaleb Isn't that true for any reason for death-whether it is because of AEF or effusion? For individuals, it is 100% risk. But for population, it still comes to 1 in 10000 risk of death with both technologies. (Simplified for discussion).
Should patients with cardiac conduction disorders (CCD) be genetically tested? Which 🧬 should be analyzed? What is the contribution of each 🧬?
Come with me to see the results of our new study published this week @JACCJournals 👇 Long 🧵 (2/16)
Advancing Science with more data from #PulsedAF#PulseSelect PFA Global Trial. Congrats to
@boersma_lucas @natale_md@atulverma_md and all co-authors. #MedtronicEmployee Prevalence, Timing, and Impact of Early Recurrence of Atrial Tachyarrh... https://t.co/4o57L99ipZ
#echofirst TEE
1️⃣A normal THEBESIAN VALVE covering the coronary sinus (CS)
2️⃣How to get the CS ostium ⬇️⏬️pushing the TEE probe from ME 4Ch into Deep esophageal view
#CardioTwitter